XERIS BIOPHARMA HOLDINGS, INC. Other Comprehensive Income (Loss), Net of Tax
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Other Comprehensive Income (Loss), Net of Tax of $14.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $14.00K, a 1300.00% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was $1.00K.
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$1.00K, a 106.67% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was $1.00K, a 80.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was -$2.00K, a 125.00% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was $8.00K.
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for fiscal 2021 was -$37.00K.
- XERIS BIOPHARMA HOLDINGS, INC. other comprehensive income (loss), net of tax for fiscal 2020 was -$37.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.00K 10-Q · filed 2026-08-06 | $15.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $1.00K 10-Q · filed 2026-08-06 | |||
| 2025-09-30 | -$1.00K 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.00K 10-Q · filed 2026-08-06 | |||
| 2024-09-30 | $15.00K 10-Q · filed 2025-11-06 | $20.00K derived: sum of 2 quarters · filed 2025-11-06 | $9.00K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $5.00K 10-Q · filed 2025-11-06 | -$6.00K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | -$11.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | -$2.00K 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $28.00K 10-Q · filed 2024-11-08 | -$21.00K derived: sum of 2 quarters · filed 2024-11-08 | -$27.00K derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | -$49.00K 10-Q · filed 2024-11-08 | -$55.00K derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | -$6.00K 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $8.00K 10-K · filed 2025-03-06 | |||
| 2022-09-30 | $15.00K 10-Q · filed 2023-11-09 | $29.00K derived: sum of 2 quarters · filed 2023-11-09 | -$6.00K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $14.00K 10-Q · filed 2023-11-09 | -$21.00K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | -$35.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | -$37.00K 10-K · filed 2024-03-06 | |||
| 2021-09-30 | -$6.00K 10-Q · filed 2022-11-09 | -$16.00K derived: sum of 2 quarters · filed 2022-11-09 | -$32.00K derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$10.00K 10-Q · filed 2022-11-09 | -$26.00K derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | -$16.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | -$37.00K 10-K · filed 2022-03-11 | |||
| 2020-09-30 | -$108.00K 10-Q · filed 2021-11-10 | -$4.00K derived: sum of 2 quarters · filed 2021-11-10 | $13.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $104.00K 10-Q · filed 2021-11-10 | $121.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $17.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |